Sanofi announced the purchase of Bioverativ, French maker of a drug treating hemophilia. The deal will close within three months and values Bioverativ at a 63% premium of their market price. Sanofi lost out on major deals in 2016 and hopes adding Bioverativ will boost its rare-disease business. Market competition is on the rise as new heavyweight firms gain traction.